Update on biologics in juvenile idiopathic arthritis

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

As experience is gained, and longer-term safety is demonstrated, it is likely that biologics will be introduced as therapy earlier in the course of patients who inadequately respond to conventional disease-modifying antirheumatic drugs.

Original languageEnglish (US)
Pages (from-to)613-618
Number of pages6
JournalCurrent Opinion in Rheumatology
Volume20
Issue number5
DOIs
StatePublished - Sep 2008

Fingerprint

Antirheumatic Agents
Juvenile Arthritis
Biological Products
Safety
Therapeutics

Keywords

  • Interleukin-1
  • Interleukin-6
  • Juvenile idiopathic arthritis
  • Tumor necrosis tor
  • Uveitis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Update on biologics in juvenile idiopathic arthritis. / Ilowite, Norman Todd.

In: Current Opinion in Rheumatology, Vol. 20, No. 5, 09.2008, p. 613-618.

Research output: Contribution to journalArticle

@article{defe317835cb4ce79d3bbf3155e20d45,
title = "Update on biologics in juvenile idiopathic arthritis",
abstract = "As experience is gained, and longer-term safety is demonstrated, it is likely that biologics will be introduced as therapy earlier in the course of patients who inadequately respond to conventional disease-modifying antirheumatic drugs.",
keywords = "Interleukin-1, Interleukin-6, Juvenile idiopathic arthritis, Tumor necrosis tor, Uveitis",
author = "Ilowite, {Norman Todd}",
year = "2008",
month = "9",
doi = "10.1097/BOR.0b013e3283060778",
language = "English (US)",
volume = "20",
pages = "613--618",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Update on biologics in juvenile idiopathic arthritis

AU - Ilowite, Norman Todd

PY - 2008/9

Y1 - 2008/9

N2 - As experience is gained, and longer-term safety is demonstrated, it is likely that biologics will be introduced as therapy earlier in the course of patients who inadequately respond to conventional disease-modifying antirheumatic drugs.

AB - As experience is gained, and longer-term safety is demonstrated, it is likely that biologics will be introduced as therapy earlier in the course of patients who inadequately respond to conventional disease-modifying antirheumatic drugs.

KW - Interleukin-1

KW - Interleukin-6

KW - Juvenile idiopathic arthritis

KW - Tumor necrosis tor

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=55249084910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249084910&partnerID=8YFLogxK

U2 - 10.1097/BOR.0b013e3283060778

DO - 10.1097/BOR.0b013e3283060778

M3 - Article

C2 - 18698187

AN - SCOPUS:55249084910

VL - 20

SP - 613

EP - 618

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 5

ER -